Should Therapeutic Drug Monitoring for Monoclonal Antibodies Remain the Exception or Become the Norm?. Issue 3 (3rd May 2016)

• Record Type: Journal Article
• Authors: Stroh, M; Lum, BL
• Is Part Of: Clinical pharmacology & therapeutics. Volume 100:Issue 3(2016:Sep.)
• Page Start: 215
• Page End: 217
• Publication Date: 2016-05-03
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.365
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Therapeutic drug monitoring (TDM) aims to maintain circulating drug concentrations at a desired level to optimize clinical outcome. The vast majority of marketed drugs do not require TDM, suggesting the clinical benefit of TDM has not been sufficiently demonstrated in most cases. With the continued emergence and prominence of monoclonal antibodies (mAbs) as drugs, especially in inflammation and cancer therapeutic areas, we are at a juncture to consider applicability of TDM for mAbs .